June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Testing the effect of RPE barrier function regulators in vitro and in vivo
Author Affiliations & Notes
  • Meili Zhu
    Medicine and Harold Hamm Diabetes Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK
  • Yun-Zheng Le
    Medicine and Harold Hamm Diabetes Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK
  • Footnotes
    Commercial Relationships Meili Zhu, None; Yun-Zheng Le, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 1770. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Meili Zhu, Yun-Zheng Le; Testing the effect of RPE barrier function regulators in vitro and in vivo. Invest. Ophthalmol. Vis. Sci. 2013;54(15):1770.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: Vascular leakage, a major pathological change in diabetic retinopathy (DR), is traditionally regarded as endothelial barrier dysfunction. However, the RPE barrier is responsible for approximately 80% of blood circulation to the retina. While a significant portion of cystoid diabetic macular edema (DME) patients have cellular lesions near the RPE, such as exudative subretinal detachment, the contribution of the RPE barrier breakdown in overall vascular leakage in DR is almost neglected. We recently developed an in vivo semi-quantitative imaging for RPE barrier-specific leakage and demonstrated a substantial contribution of the RPE barrier breakdown in diabetic rodents (IOVS 52: 2160, 2011). To assess the feasibility of our assay in screening/verifying therapeutic agents for diabetes-induced RPE barrier breakdown, we performed a proof-of-concept study and found that in vivo imaging analysis correlated well with in vitro RPE barrier function assay.

Methods: Blood-retina barrier (BRB) function regulators, such as vascular endothelial growth factor (VEGF) and extracellular-signal-regulated kinase (ERK) inhibitor, were used to measure the trans-epithelial resistance (TER) in ARPE-19 cells under various culture conditions. High molecular weight fluorescein isothiocyanate (FITC)-dextran was used to determine the effect of these BRB function regulators on RPE barrier in hypoxic mice generated with oxygen-induced retinopathy (OIR).

Results: VEGF caused a significant reduction of TER in ARPE-19 cultures. This observation correlated with the increase of severe RPE barrier break points in OIR mice supplemented with VEGF intravitreally. Likewise, ERK inhibitor, which was suggested to play a role in downregulating VEGF, increased TER in hypoxic ARPE-19 cultures and reduced the frequency of severe RPE barrier break points in OIR mice. In vivo testing RPE barrier function for other BRB regulators is in progress.

Conclusions: We have demonstrated that our in vivo RPE barrier function analysis correlates well with traditional in vitro RPE barrier function assay. Therefore, a combination of in vivo and in vitro assays for RPE barrier function may be useful for mechanistic studies and for screening drugs with therapeutic potentials for RPE barrier breakdown in DME, a major vision loss in DR.

Keywords: 499 diabetic retinopathy • 505 edema • 697 retinal detachment  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×